Tyrogenex closes enrolment in Phase II trial of X-82 to treat wAMD

US-based biopharmaceutical company Tyrogenex has completed patient enrolment in the Phase II clinical trial (APEX) of X-82 (vorolanib) for the treatment of wet age-related macular degeneration (wAMD).
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news